コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ise, sepsis, cardiac surgery, or exposure to nephrotoxins.
2 ESRD risk among cohorts exposed to potential nephrotoxins.
3 ecognition of sepsis as well as avoidance of nephrotoxins.
4 unilateral ureteral obstruction, ischemia or nephrotoxins.
5 , vancomycin dose, and number of concomitant nephrotoxins.
8 ischemia reperfusion, sepsis, or exposure to nephrotoxins and is associated with a high rate of morta
9 ntensive care unit level of care, receipt of nephrotoxins, and hospital, IV vancomycin plus piperacil
10 osphorylation; moreover, they are evident in nephrotoxin- and ischemia/reperfusion-induced injury, di
11 , we injured human kidney organoids with the nephrotoxin cisplatin (5 muM) followed by 5 x 10(4) USC
13 dition, recent information about the classic nephrotoxins (cisplatin, amphotericin B, and aminoglycos
14 ogenase (LDH) release, when exposed to known nephrotoxins, cisplatin and aristolochic acid, which are
19 I receptor blockers), avoidance of potential nephrotoxins (eg, nonsteroidal anti-inflammatory drugs),
25 idney injury, which can arise in response to nephrotoxins, sepsis, and ischemia/reperfusion, and in c
26 ting of supportive measures and avoidance of nephrotoxins significantly reduced the occurrence of mod